A BIRC5High COD1Low Cancer Tissue Phenotype Indicates Poorer Prognosis of Metastatic Breast Cancer Patients. (May 2022)

• Record Type: Journal Article
• Authors: Bai, Yujie; Yuan, Feng; Yu, Jing; Si, Yibei; Zheng, Yiwen; Li, Dongqing
• Is Part Of: Cancer informatics. Volume 21(2022)
• Publication Date: 2022-05
• Subjects: Breast cancer -- BIRC5 -- CDO1 -- prognostic prediction; Bioinformatics -- Periodicals; Biology -- Data processing -- Periodicals; Cancer -- Periodicals; Cancer -- Research -- Periodicals; Computational biology -- Periodicals; 570.285
• DOI: 10.1177/11769351221096655
• Languages: English
• ISSNs: 1176-9351

Abstract

Extensive data research is helpful to find sensitive biomarkers for prognostic prediction of metastatic breast cancer. Through analyzing multiple GEO datasets, literature retrieval, and verified in GEPIA datasets, we identify BIRC5 (Baculoviral IAP repeat containing 5) and CDO1 (Cysteine dioxygenase type 1) as DEGs (differentially expressed genes) between breast tumor and normal tissue and DEGs between metastatic breast cancer and breast cancer in situ. Then, we performed a series of in silico studies on BIRC5 and CDO1 using online tools including the UALCAN, TIMER, TCGA-BRCA, LinkedOmics Kaplan-Meier Plotter, and an R script for analysis. To verify the association of 2 genes expression and patients' clinical data, we detected BIRC5 and CDO1 mRNA in the tissue of 48 breast cancer patients. The results showed the tumor with BIRC5 high CDO1 low expression generally indicated patients' shorter overall (OS) and relapse-free survival (RFS). Specifically, BIRC5 and CDO1 levels significantly affect OS or RFS in patients with Lymph node metastasis and molecular subtypes of TNBC (triple-negative breast cancer) and Luminal A. A BIRC5 high tumor displayed a purer tumor purity and expressed more KIR receptors on NK cells while activating more FOXP3 + CD25 + Treg cells. The CDO1 low tumors infiltrated with more immunocytes leading to less tumor purity. In our verified experiment, BIRC5 mRNA level in patients with stage III and over was significantly higher than in patients with stage 0 to II, but there were no significant differences among molecular subtyping groups; TNBC tissue expressed lower CDO1 mRNA level than HER2 + and Luminal type cancer tissue. In conclusion, a BIRC5 high CDO1 low expression type in breast cancer tissue indicates a poorer prognosis of patients. The potential mechanism might be increased BIRC5 expression in cancer tissue is likely to accompany NK cells inhibition, activating more Treg cells, and lacking effective CD8 + T cells proliferation. Meanwhile, CDO1 level is positively related to more immunocytes infiltration.